Get to Know Dr. Charles Staley
Surgical oncologist Dr. Charles Staley specializes in the treatment of peritoneal surface malignancies, including malignant mesothelioma cancer.
At the Winship Cancer Institute at Emory University, Staley also serves as director for the hyperthermic intraperitoneal chemotherapy program, which has played a key role in advancing peritoneal mesothelioma treatment for many patients with the cancer.
Staley often uses the procedure, also known as HIPEC, in combination with cytoreductive surgery for several abdominal cancers. This has led to survival rates of three to 10 years and beyond.
He is leader of the surgical oncology team and also serves as the chief quality officer. For many years he has tracked and improved patient services at Winship.
Staley has been with the Emory University School of Medicine since 1995, after completing his surgical oncology fellowship at the prestigious MD Anderson Cancer Center.
His research has focused on translational studies and gastrointestinal cancers. He has investigated gene therapy, radiofrequency ablation with intra-arterial chemotherapy and the use of nanotechnology.
Specialties of Dr. Charles Staley
- Peritoneal mesothelioma
- Colorectal cancer
- Esophageal cancer
- Gastrointestinal stromal tumor
- Pancreatic cancer
- Stomach cancer
- Cytoreductive surgery
- Translational research
Dr. Charles Staley’s Experience and Medical Education
- Winship Cancer Institute, Emory University
- Dartmouth Medical School (M.D.)
- MD Anderson Cancer Center (Fellowship)
- University Health Center of Pittsburgh (Residency)
Awards and Other Recognitions
- Atlanta’s Top Doctors, Atlanta Magazine
- Resident Teaching Award, Emory University
- Distinguished Faculty, Emory University
- Veterans Administration oncology grant reviewer
- External auditor, Eastern Cooperative Oncology Group
- Invited speaker, National Institutes of Health science conference
Publications of Dr. Charles Staley
- Powers, B. et al. (2020, April 21). Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated With Prohibitive Complications: Results of a Multi-institutional Retrospective Study. Annals of Surgical Oncology.
- Enofe, N. et al. (2020, March 31). Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer and Overall Survival: A National Cancer Database Study. Journal of Surgical Research.
- Gamboa, A. et al. (2020, January). Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology.
- Russell, M.C. & Staley, C.A. (2016, October 12). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma. Journal of Oncology Practice.
Thank you for your feedback. Would you like to speak with a Patient Advocate?